Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques.

MLA

Zabaleta, Nerea, et al. “Durable Immunogenicity, Adaptation to Emerging Variants, and Low-Dose Efficacy of an AAV-Based COVID-19 Vaccine Platform in Macaques.” Molecular Therapy : The Journal of the American Society of Gene Therapy, vol. 30, no. 9, Sept. 2022, pp. 2952–67. EBSCOhost, https://doi.org/10.1016/j.ymthe.2022.05.007.

APA

Zabaleta, N., Bhatt, U., Hérate, C., Maisonnasse, P., Sanmiguel, J., Diop, C., Castore, S., Estelien, R., Li, D., Dereuddre-Bosquet, N., Cavarelli, M., Gallouët, A.-S., Pascal, Q., Naninck, T., Kahlaoui, N., Lemaitre, J., Relouzat, F., Ronzitti, G., Thibaut, H. J., … Vandenberghe, L. H. (2022). Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Molecular Therapy : The Journal of the American Society of Gene Therapy, 30(9), 2952–2967. https://doi.org/10.1016/j.ymthe.2022.05.007

Chicago

Zabaleta, Nerea, Urja Bhatt, Cécile Hérate, Pauline Maisonnasse, Julio Sanmiguel, Cheikh Diop, Sofia Castore, et al. 2022. “Durable Immunogenicity, Adaptation to Emerging Variants, and Low-Dose Efficacy of an AAV-Based COVID-19 Vaccine Platform in Macaques.” Molecular Therapy : The Journal of the American Society of Gene Therapy 30 (9): 2952–67. doi:10.1016/j.ymthe.2022.05.007.